A practical guide to the use of eltrombopag in children with chronic immune thrombocytopenia

Pediatr Hematol Oncol. 2017 Mar;34(2):73-89. doi: 10.1080/08880018.2017.1313918. Epub 2017 May 24.


Introduction: Pediatric immune thrombocytopenia (ITP) may be associated with significant burden on children and their parents/caregivers. Thrombopoietin (TPO) receptor agonists (RAs) have been used to treat adult patients with chronic ITP (cITP) for nearly a decade and following pediatric studies Eltrombopag has been recently approved for pediatric cITP in the United States and Europe. TPO-RA s may help reduce the risk of bleeding and the need for conventional ITP therapies.

Review: In this review, the clinical data demonstrating the efficacy and safety of TPO-RAs in pediatric ITP are evaluated, key recommendations regarding safe administration of eltrombopag are provided, and potential future directions in management of pediatric ITP are discussed.

Keywords: Eltrombopag; pediatric; romiplostim; thrombocytopenia; thrombopoietin receptor agonists.

Publication types

  • Review

MeSH terms

  • Adolescent
  • Benzoates / therapeutic use*
  • Child
  • Child, Preschool
  • Chronic Disease
  • Female
  • Humans
  • Hydrazines / therapeutic use*
  • Infant
  • Infant, Newborn
  • Male
  • Practice Guidelines as Topic
  • Purpura, Thrombocytopenic, Idiopathic / drug therapy*
  • Pyrazoles / therapeutic use*


  • Benzoates
  • Hydrazines
  • Pyrazoles
  • eltrombopag